These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16829618)

  • 1. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.
    Ruijne N; Lea RA; O'Hallahan J; Oster P; Martin D
    Clin Vaccine Immunol; 2006 Jul; 13(7):797-801. PubMed ID: 16829618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
    Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
    Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
    Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.
    Sandbu S; Feiring B; Oster P; Helland OS; Bakke HS; Naess LM; Aase A; Aaberge IS; Kristoffersen AC; Rydland KM; Tilman S; Nøkleby H; Rosenqvist E
    Clin Vaccine Immunol; 2007 Sep; 14(9):1062-9. PubMed ID: 17634513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules.
    Gioia CA; de Sousa AB; Cruz SC; Junior FC; Andrade AF; Sassi RM; Frasch CE; Milagres LG
    FEMS Immunol Med Microbiol; 2005 Apr; 44(1):35-42. PubMed ID: 15780576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
    Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
    Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
    Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life.
    Nair N; Gans H; Lew-Yasukawa L; Long-Wagar AC; Arvin A; Griffin DE
    J Infect Dis; 2007 Nov; 196(9):1339-45. PubMed ID: 17922398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
    Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
    J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.
    Feiring B; Fuglesang J; Oster P; Naess LM; Helland OS; Tilman S; Rosenqvist E; Bergsaker MA; Nøkleby H; Aaberge IS
    Clin Vaccine Immunol; 2006 Jul; 13(7):790-6. PubMed ID: 16829617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.
    Vermont CL; van Dijken HH; de Groot R; van den Dobbelsteen GP
    Pediatr Res; 2005 Jul; 58(1):149-52. PubMed ID: 15774845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.
    Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG
    Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.
    Pichichero M; Papa T; Blatter M; Mitchell D; Kratz R; Sneed J; Bassily E; Casey J; Gilmet G
    Pediatr Infect Dis J; 2006 Nov; 25(11):995-1000. PubMed ID: 17072120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
    Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
    Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine.
    Clarke P; Robinson MJ; Ahmad I; Bedford-Russell AR; Connell JE; Powell PJ; Heath PT
    Vaccine; 2006 Apr; 24(16):3273-8. PubMed ID: 16472548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.